Table 5. Review of treatments and survival outcomes of patients with biliary atresia in studies published after 2010.
| Country of study | Author, year | Study period | No. of patients | Sex ratio (M:F) | Procedure | Median age at HPE, days | Native liver survival, year (%) | Overall survival, year (%) |
|---|---|---|---|---|---|---|---|---|
| Middle East | ||||||||
| Bahrain (present study) | Isa et al, 2023 | 1993–2021 | 26 | 11:15 | HPE: 23, LT: 3 | 61 | 5 (53.8) | 5 (65.4) |
| Saudi Arabia | Holdar et al,14 2019 | 2008–2015 | 21 | 11:10 | HPE: 12, LT: 9 | 73 | 4 (14.3) | 4 (81) |
| Saudi Arabia | Khayat et al,15 2021 | 1999–2017 | 23 | 10:13 | HPE | 77 | (56) | (69.5) |
| Iran | Naghashi et al,16 2020 | 2006–2017 | 90 | 44:50 | HPE: 71 | 64.7† | 5 (40) | NR‡ |
| Egypt | Gad et al,17 2021 | 2000–2019 | 410 | 186:224 | HPE | 65 | 5 (49.8) | 5 (51.5) |
| Asia-Pacific | ||||||||
| Hong Kong | Chung et al,18 2021 | 1980–2017 | 231 | 97:134 | HPE | 59 | 10 (70.7) | NR |
| China | Wang et al,30 2019 | 2009–2012 | 139 | 77:62 | HPE | 78.3† | 5 (58) | NR |
| India | Redkar et al,31 2017 | 2000–2014 | 121 | 75:46 | HPE | 96 | 1 (43.8) | NR |
| Europe | ||||||||
| Italy | Parolini et al,32 2019 | 1975–1996 | 174 | 91:83 | HPE | 60 | 5 (41) | NR |
| Nordic countries | Pakarinen et al,20 2018 | 2005–2016 | 154 | 71:83 | HPE: 148, LT: 6 | 64 | 5 (53) | 5 (88) |
| Netherlands | de Vries et al,5 2012 | 1987–2008 | 214 | 110:104 | HPE | 59 | 4 (46 ± 4) | 4 (73 ± 3) |
| France | Chardot et al,8 2013 | 1986–2009 | 1107 | NR | HPE: 1044 | 59 | 5 (40) | 5 (81) |
| England and Wales | Davenport et al,33 2011 | 1999–2009 | 443 | NR | HPE: 424, LT: 15 | 54 | 5 (46) | 5 (90) |
| Africa | ||||||||
| South Africa | De Maayer et al,34 2017 | 2009–2012 | 70 | 13:30 | HPE: 43 | 64 | 2 (32.6) | NR |
†mean days; ‡no record; HPE: hepatic portoenterostomy (Kasai procedure); M:F: male:female; LT: liver transplant.